STOCK TITAN

Bone Biologics Corp - BBLG STOCK NEWS

Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.

Bone Biologics Corp (BBLG) pioneers regenerative bone repair solutions using its UCLA-licensed ucb-1™ platform. This page aggregates all official news and press releases, offering stakeholders a centralized hub for tracking advancements in orthobiologics and surgical innovation.

Access real-time updates on clinical trial milestones, regulatory submissions, and strategic partnerships that define BBLG's role in advancing bone regeneration. Our curated feed ensures investors stay informed about material developments impacting the company's trajectory in biotechnology.

Key coverage areas include progress in spinal surgery therapeutics, orthopedic procedure innovations, and collaborative research with leading medical institutions. Each update is vetted for accuracy, providing reliable insights into product pipelines and intellectual property achievements.

Bookmark this page for streamlined access to Bone Biologics' latest announcements. Enable alerts to receive immediate notifications on critical disclosures, ensuring you remain ahead in monitoring this dynamic sector.

Rhea-AI Summary

Bone Biologics (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, has appointed Phillip T. Meikle to its Board of Directors. Mr. Meikle brings over 30 years of commercial experience in the orthopedic and spine industry. He succeeds Don R. Hankey, who retired after seven years of service. The board remains at four directors.

Mr. Meikle was previously the president and CEO of Biosystems of New England, Inc., an orthopedic distribution company he founded in 1992 and sold to Stryker in 2019. He has been a consultant to Stryker Spine for the past five years. His company served as a distributor for Stryker Spine from 2002 to 2019 and for Medtronic Spine from 1992 to 2002.

Jeffrey Frelick, president and CEO of Bone Biologics, expressed enthusiasm about Mr. Meikle's appointment, citing his extensive experience with orthopedic and spine products as particularly valuable as the company develops NB1 for spinal fusion patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
management
-
Rhea-AI Summary

Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. Jeffrey Frelick, the company's CEO, will deliver a virtual presentation, which will be accessible online starting September 9th at 7:00 a.m. Eastern time.

The presentation will remain available on the company's website for a time. Bone Biologics' management team will also be available for virtual one-on-one meetings throughout the conference. Institutional investors and industry professionals can choose to attend the conference either virtually or in-person at the Lotte New York Palace Hotel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
-
Rhea-AI Summary

Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced a $2.1 million gross proceeds from the exercise of warrants. The company entered into a definitive agreement for the exercise of existing warrants to purchase 781,251 shares of common stock at $2.43 per share. In exchange, Bone Biologics will issue new unregistered warrants to purchase up to 1,562,502 shares of common stock at $2.00 per share.

The new warrants will have varying terms: half with a five-year term and half with an eighteen-month term. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around August 2, 2024. Bone Biologics plans to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Bone Biologics (Nasdaq: BBLG) has commenced the first treatments in its pilot clinical study evaluating the NB1 bone graft device for spine fusion in patients with degenerative disc disease (DDD). The study, involving 30 patients, aims to assess the safety, effectiveness, fusion success, pain relief, functional improvement, and adverse events of NB1. The first two patients were treated in Australia. The U.S. FDA has reviewed and agreed upon the study's design, which could support a pivotal U.S. trial. CEO Jeffrey Frelick highlighted NB1's potential to address a $3 billion global spine fusion market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.09%
Tags
-
Rhea-AI Summary
Bone Biologics Corporation (BBLG) closes public offering, raising $2.0 million for clinical trials and patent portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
-
Rhea-AI Summary
Bone Biologics Corporation (BBLG) announces the pricing of a public offering of 781,251 shares of common stock and warrants at $2.56 per share, aiming to raise capital for its orthobiologic products in spine fusion markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
Rhea-AI Summary
Bone Biologics Corporation (BBLG) progresses with human clinical testing for spinal fusion product candidate NB1, with three hospital sites engaged in the pilot trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Summary
Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) appoints Robert E. Gagnon, a seasoned finance and business operations professional, to its board of directors. With over 20 years of experience in leading global finance operations and serving in executive roles at various life sciences companies, Mr. Gagnon's appointment is expected to bring valuable expertise in clinical stage companies, capital raising, and commercial organizations to support Bone Biologics' growth and its pilot study with NB-1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
management
-
Rhea-AI Summary
Bone Biologics Corporation (BBLG) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The company's common stock will continue to be listed on The Nasdaq Capital Market, but will remain under Nasdaq’s discretionary panel monitor until June 28, 2024. Bone Biologics failed to meet the closing bid price of $1.00 for 30 consecutive business days but regained compliance by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, as of January 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
Rhea-AI Summary
Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) announces a planned 1-for-8 reverse stock split of its shares of common stock, effective December 20, 2023. Stockholders approved the split at a special meeting on December 12, 2023. The reverse stock split aims to adjust the stock price and number of outstanding shares, with the new CUSIP number of the common stock being 098070501.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
Bone Biologics Corp

Nasdaq:BBLG

BBLG Rankings

BBLG Stock Data

2.22M
3.27M
2.13%
2.14%
5.91%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
BURLINGTON